HealthQuill Biogen Inc
Sage Therapeutics Inc.’s experimental drug failed to meet its main goal of treating mild dementia due to Alzheimer's disease and the US, Cambridge-headquartered company has halted its trials.
Drugs Health Pharma

Sage Therapeutics halts trials of experimental drug to treat dementia

Sage Therapeutics Inc.’s experimental drug failed to meet its main goal of treating mild dementia due to Alzheimer's disease and the US, Cambridge-headquartered.

Read More
An oral investigational drug jointly developed by Biogen Inc., and Sage Therapeutics Inc., failed to stop essential tremors in patients, forcing the companies to halt the trial.
Drugs Health Pharma

Biogen, Sage halt tremor trial after ‘disappointing’ oral drug results

An oral investigational drug jointly developed by Biogen Inc., and Sage Therapeutics Inc., failed to stop essential tremors in patients, forcing the companies.

Read More
The European Commission has granted marketing approval for Biogen Inc.’s therapy for the treatment of a form of amyotrophic lateral sclerosis.
Drugs Health Pharma

Biogen’s ALS drug gets European Commission’s marketing nod

The European Commission has granted marketing approval for Biogen Inc.’s therapy for the treatment of a form of amyotrophic lateral sclerosis.

Read More
Biogen Inc., a US biotechnology company, has got marketing authorisation from the European medicines regulator for its drug to treat neurodegenerative disease, amyotrophic lateral sclerosis.
Drugs Health Pharma

European regulator backs Biogen’s drug for amyotrophic lateral sclerosis

HQ Team February 24, 2024: Biogen Inc., a US biotechnology company, has got marketing authorisation from the European medicines regulator for its drug.

Read More
Biogen, a US-based biotechnology company, will discontinue the development and commercialisation of its Alzheimer’s treatment and terminate its post-approval study as it failed to rope in a partner to cut costs of obtaining standard regulatory approval.
Drugs Health Pharma

Biogen abandons Alzheimer’s drug Aduhelm to focus on Leqembi

Biogen, a US-based biotechnology company, will discontinue the development and commercialisation of its Alzheimer’s treatment and terminate its post-approval study as it failed.

Read More
Quest Diagnostics, a New Jersey, US-based clinical laboratory company, has started selling the first blood testing kits for detecting Alzheimer’s disease early.
Drugs Health Pharma

Quest Diagnostics unveils direct-to-customer tests for Alzheimer’s 

HQ Team August 1, 2023: Quest Diagnostics, a New Jersey, US-based clinical laboratory company, has started selling the first blood testing kits for.

Read More
Biogen Inc., a US-based biotechnology company, will acquire Reata Pharmaceuticals for $7.3 billion to expand its neurological portfolio, according to a company statement
Drugs Health Pharma

Biogen Inc. to buy US-based Reata Pharmaceuticals for $7.3 billion

HQ Team July 29, 2023: Biogen Inc., a US-based biotechnology company, will acquire Reata Pharmaceuticals for $7.3 billion to expand its neurological portfolio,.

Read More
Japan’s Eisai Co and Biogen Inc., have submitted a marketing authorisation application with the South Korean health authority for leqembi, an investigational drug to treat early onset of Alzheimer’s disease.
Drugs Health Medical Pharma

Japan’s Eisai seeks marketing nod for Alzheimer’s drug in South Korea

HQ Team June 8, 2023: Japan’s Eisai Co and Biogen Inc., have submitted a marketing authorisation application with the South Korean health authority.

Read More
The US Food and Drug Administration has cleared Biogen Inc’s drug, branded as Qalsody, to treat amyotrophic lateral sclerosis (ALS), an aggressive and rare form of the disease in adults.
Drugs Health Medical Pharma

Biogen’s sclerosis drug gets FDA’s fast approval clearance

HQ Team April 26, 2023: The US Food and Drug Administration has cleared Biogen Inc’s drug, branded as Qalsody, to treat amyotrophic lateral.

Read More
The FDA has granted accelerated approval for an intravenous drug to treat Alzheimer's Disease, according to a statement.
Drugs Pharma

FDA gives accelerated approval for Alzheimer’s drug

The FDA has granted accelerated approval for an intravenous drug to treat Alzheimer's Disease, according to a statement.

Read More
X